CADL
$5.17
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.
Recent News
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene besadenovec (CAN-2409) in patients with advanced non-small cell lung cancer (NSCLC) who had previously shown an inadequate response to...
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances
Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential commercialization, outlining new phase 3 trials and a planned regulatory filing while reporting its fourth quarter and full-year 2025 financial results. “During the quarter, we...
Candel Therapeutics prices $100M public offering
Candel Therapeutics Inc (NASDAQ:CADL) told investors on Thursday it has priced its previously disclosed public offering of about 18.3 million shares at $5.45 per share. The clinical-stage biopharmaceutical company said the offering is expected to generate gross proceeds of about $100 million,...
Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering
Candel Therapeutics Inc (NASDAQ:CADL) on Thursday announced two financing initiatives to support the potential US launch of its cancer therapy aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer: a $100 million royalty funding agreement with RTW...
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term
With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics...